Kura Oncology
KURA
199 hedge funds and large institutions have $2.12B invested in Kura Oncology in 2020 Q4 according to their latest regulatory filings, with 54 funds opening new positions, 75 increasing their positions, 56 reducing their positions, and 15 closing their positions.
260% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 15
258% more call options, than puts
Call options by funds: $23.5M | Put options by funds: $6.58M
34% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 56
29% more capital invested
Capital invested by funds: $1.65B → $2.12B (+$476M)
23% more funds holding
Funds holding: 162 → 199 (+37)
4.74% more ownership
Funds ownership: 95.62% → 100.36% (+4.7%)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$66M |
| 2 |
RI
RTW Investments
New York
|
+$59.8M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$55M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$37.2M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$36.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$99.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$46M |
| 3 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$25.1M |
| 4 |
CTA
Carillon Tower Advisers
St. Petersburg,
Florida
|
-$20.5M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$18.4M |
KURA Hedge Fund Activity: Q4 2020 in Review
199 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q4 2020, worth a combined $2.12B — up 29% from $1.65B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new KURA positions and 15 closed out — a net gain of 39 holders — while 75 added to existing stakes and 56 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $66M. The largest seller was EcoR1 Capital, cutting an estimated $99.6M.
- 199 institutional investors held Kura Oncology (KURA) as of Q4 2020, up from 162 in Q3 2020.
- Funds reported $2.12B of Kura Oncology stock for Q4 2020, up 29% quarter-over-quarter.
- 54 funds opened new Kura Oncology positions in Q4 2020 and 15 closed out, a net change of +39 holders.
- The largest Kura Oncology buyer in Q4 2020 was Fidelity Investments, an estimated $66M added.
- The largest Kura Oncology seller in Q4 2020 was EcoR1 Capital, an estimated $99.6M sold.
Based on aggregated 13F filings for Q4 2020.